7 Analysts Have This To Say About NeoGenomics

NeoGenomics, Inc. -1.74%

NeoGenomics, Inc.




Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 1 2 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 0 1 0 0
3M Ago 2 1 1 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.14, a high estimate of $21.00, and a low estimate of $16.00. Experiencing a 4.53% decline, the current average is now lower than the previous average price target of $19.00.

price target chart

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Mike Matson Needham Maintains Buy $21.00 -
Tejas Savant Morgan Stanley Raises Equal-Weight $17.00 $16.00
Mike Matson Needham Maintains Buy $21.00 -
Tejas Savant Morgan Stanley Lowers Equal-Weight $16.00 $18.00
Matthew Sykes Goldman Sachs Lowers Buy $17.00 $19.00
Matthew Sykes Goldman Sachs Lowers Buy $17.00 $19.00
David Westenberg Piper Sandler Lowers Overweight $18.00 $23.00

Key Insights:

  • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NeoGenomics. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of NeoGenomics compared to the broader market.
  • Price Targets: Delving into movements, analysts provide estimates for the future value of NeoGenomics's stock. This analysis reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NeoGenomics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on NeoGenomics analyst ratings.

Discovering NeoGenomics: A Closer Look

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Financial Milestones: NeoGenomics's Journey

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: NeoGenomics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 17.99%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -12.19%, the company may face hurdles in effective cost management.

Return on Equity (ROE): NeoGenomics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.95%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): NeoGenomics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.1%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.64, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: Simplified

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via